AUTHORS
Amirsaman Ashtari, PhD, Navika Shukla, MD2, Lena Osswald, MD3, Takeshi Sugio, MD, PhD4, Stefan Alig, MD5, Joe Gaillard Schroers-Martin, MD6, Ash A. Alizadeh, MD, PhD7, Henning Stehr, MD8, Mohammad Shahrokh Esfahani, PhD9
AFFILIATIONS
1 Stanford University, Palo Alto, United States
2 Stanford University, Palo Alto, United States
3 Stanford University, Palo Alto, United States
4 Stanford University, Palo Alto, United States
5 University Hospital Essen, Essen, Germany
6 Stanford University, Palo Alto, United States
7 Stanford University, Palo Alto, United States
8 Stanford University, Palo Alto, United States
9 Stanford University, Palo Alto, United States
ABSTRACT
Background. Immune-receptor clonality testing is often used for diagnosis and monitoring of lymphoid malignancies but generally requires dedicated V(D)J assays to interrogate B- and T-cell receptor (BCR/TCR) recombinations. We developed J-TRACE to recover clonality information from Heme-STAMP, Stanford’s institutional comprehensive tumor-genotyping panel for hematolymphoid malignancies, by exploiting its IGH and TCR J-segment coverage together with off-target/unmapped reads, and now share this resource.
Methods. We analyzed 1,328 tissue specimens from 977 Heme-STAMP profiled patients at ~2,000× median depth. T-cell lymphomas, DLBCL, FL, and myeloma comprised the most prevalent lymphoid tumor types accounting for ~30% of cases. Of these 1,328 cases, 942 (71%) had clonal status available by an orthogonal assay (Invivoscribe LymphoTrack) for training/validation, with the remaining 386 (29%) used for additional validation by malignancy type.
We developed J-TRACE to retrieve reads overlapping J segments, their mates, unmapped reads, and off-target reads at V loci, and to refine mappings to 1,169 IMGT V- and J-region alleles by BLAST, assembling fixed VJ-pairings with per-chain V×J fragment-count matrices for TRB/G and IGH/K. These count matrices were further summarized into 76 to 392 features to train a probabilistic BCR/TCR clonality model through an ensemble machine learning framework. The performance of J-TRACE was then evaluated by cross-validation. As a comparison, MiXCR was benchmarked on identical reads from 400 balanced specimens.
Results. For TCR clonality analysis (TRB/G), we studied 842 specimens (337 nonclonal, 128 oligoclonal, 377 clonal), and for BCR clonality analysis (IGH/K), we studied 358 specimens (213 nonclonal, 4 oligoclonal, 141 clonal). Among specimens with TRB scores, maximum clone abundance increased monotonically from 7.8% in nonclonal to 15% in oligoclonal and 26.8% in clonal specimens (Kruskal-Wallis P<<0.001), supporting oligoclonality as an intermediate state; similar trends were seen for BCR clonality.
Among features used by J-TRACE, maximal VxJ clone fraction (TRB) and VxJ Gini (TRG/IGH/IGK) had best clonality discriminatory power (corresponding AUCs of 0.801, 0.736, 0.607, 0.683), with rising performance seen as a function of junctional depth. J-TRACE-TCR achieved AUC ~0.86, with a paired AUC gain of 0.033 over TRB maximal clone fraction, corresponding to 68% sensitivity at 90% specificity. J-TRACE-BCR achieved an AUC of 0.76. Gains were greatest in bone marrow and FFPE specimens, whereas high-depth peripheral-blood specimens derived little incremental benefit.
Against MiXCR on identical reads, repertoire burden correlated strongly (Spearman ρ=0.74; p<0.001); at matched V×J resolution, J-TRACE and MiXCR were statistically equivalent. Full-CDR3 MiXCR had numerically but not statistically higher AUC for V×J representation than J-TRACE (0.862 vs 0.826; P=0.22), indicating that capture and V×J resolution, rather than assignment, are limiting. Additional favorable benchmarking comparisons to existing methods including MiXCR and SABER for the entire cohort will be presented.
Finally, we applied J-TRACE to the remaining 386 specimens, consisting of TCL (n=63), DLBCL (n=160), FL (n=94), and MCL (n=69). We observed a striking contrast in inferred BCR clonality among B-cell malignancies of decreasing tumor purity (MCL=0.957, DLBCL=0.687, FL=0.502; p=6.5 × 10⁻¹⁸). Conversely, the inferred TCR clonality was significantly higher in TCL tumors compared with B-cell neoplasms (0.411 versus 0.291; p=0.0316).
Conclusions: J-TRACE allows accurate and quantitative T- and B-cell clonality measurements from routine comprehensive genome profiling, without an additional assay, tissue requirement, or sequencing run. J-anchored capture preserves an ordered biological signal enabling J-TRACE to achieve performance improvements. While J-TRACE is not intended to replace dedicated clonality testing, as a shared resource (URL pending), it accurately identifies likely clonal, likely nonclonal, and lower-confidence specimens for confirmatory standard of care testing.
DISCLOSURES
Amirsaman Ashtari, PhD: No relevant conflicts of interest to declare.